Fani, M.; Weingaertner, V.; Kolenc Peitl, P.; Mansi, R.; Gaonkar, R.H.; Garnuszek, P.; Mikolajczak, R.; Novak, D.; Simoncic, U.; Hubalewska-Dydejczyk, A.;
et al. Selection of the First 99mTc-Labelled Somatostatin Receptor Subtype 2 Antagonist for Clinical Translation—Preclinical Assessment of Two Optimized Candidates. Pharmaceuticals 2021, 14, 19.
https://doi.org/10.3390/ph14010019
AMA Style
Fani M, Weingaertner V, Kolenc Peitl P, Mansi R, Gaonkar RH, Garnuszek P, Mikolajczak R, Novak D, Simoncic U, Hubalewska-Dydejczyk A,
et al. Selection of the First 99mTc-Labelled Somatostatin Receptor Subtype 2 Antagonist for Clinical Translation—Preclinical Assessment of Two Optimized Candidates. Pharmaceuticals. 2021; 14(1):19.
https://doi.org/10.3390/ph14010019
Chicago/Turabian Style
Fani, Melpomeni, Viktoria Weingaertner, Petra Kolenc Peitl, Rosalba Mansi, Raghuvir H. Gaonkar, Piotr Garnuszek, Renata Mikolajczak, Doroteja Novak, Urban Simoncic, Alicja Hubalewska-Dydejczyk,
and et al. 2021. "Selection of the First 99mTc-Labelled Somatostatin Receptor Subtype 2 Antagonist for Clinical Translation—Preclinical Assessment of Two Optimized Candidates" Pharmaceuticals 14, no. 1: 19.
https://doi.org/10.3390/ph14010019
APA Style
Fani, M., Weingaertner, V., Kolenc Peitl, P., Mansi, R., Gaonkar, R. H., Garnuszek, P., Mikolajczak, R., Novak, D., Simoncic, U., Hubalewska-Dydejczyk, A., Rangger, C., Kaeopookum, P., & Decristoforo, C.
(2021). Selection of the First 99mTc-Labelled Somatostatin Receptor Subtype 2 Antagonist for Clinical Translation—Preclinical Assessment of Two Optimized Candidates. Pharmaceuticals, 14(1), 19.
https://doi.org/10.3390/ph14010019